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Purpose	The COVID-19 pandemic continues to have major and long-lasting impacts on health care delivery
and mental health. As health care shifted to telehealth, legislation was adjusted to expand telehealth
allowances, creating a unique opportunity to elucidate outcomes. The aim of this study was to assess
long-term patient and clinician satisfaction and outcomes with virtual behavioral health.
Methods	Data were obtained over 16 months from surveys to patients and clinicians receiving/providing virtual
treatment. Outcomes data also were collected from medical records of adults receiving in-person
and virtual behavioral health treatment. Data were summarized using descriptive statistics. Groups
were compared using various chi-squared tests for categorical variables, Likert response trends over
time, and conditional independence, with Wilcoxon rank-sum or Jonckheere trend test used to assess
continuous variables. P-values of ≤0.05 were considered statistically significant.
Results 	Patients gave high ratings to virtual treatment and indicated a preference for virtual formats. Both patient
and clinician preference for virtual visits increased significantly with time, and many clinicians perceived
virtual services to be equally effective to in-person. Virtual programs had higher completion rates,
attendance rates, and number of treatment visits, suggesting that virtual behavioral health had equivalent
or better outcomes to in-person treatment and that attitudes toward telehealth changed over time.
Conclusions	If trends found in this study continue, telehealth may emerge as a preferred option long term This is
important considering the increase in mental health needs associated with the COVID-19 pandemic
and the eventuality that in-person restrictions ease as the pandemic subsides. (J Patient Cent Res Rev.
2022;9:158-165.)
Keywords	telehealth; telemedicine; patient and clinician satisfaction; behavioral health; COVID-19; no-shows;
hybrid virtual

C

OVID-19 has significantly impacted the mental
health of Americans and prompted major changes
in behavioral health utilization.1,2 Psychological
illnesses increased3,4 — both as direct and indirect products
of COVID-191,5 — and symptoms worsened for patients
with preexisting psychiatric illness,4,6,7 significantly
increasing the need for behavioral health services.
Historically, most behavioral health treatments have been
conducted in-person.2 However, COVID-19 pressured
health systems to incorporate telehealth options.8,9
Clinics transitioned quickly, clinicians adapted to virtual
services while upholding quality of care, and the scope of

insurance coverage expanded to encompass telehealth.10,11
Overall, patient and physician satisfaction for telehealth
has been positive across medical specialties,11-16 which
is critical given established correlations between patient
satisfaction and outcomes.17-19
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The purpose of this quality-of-care study was to elucidate
patient and clinician satisfaction with virtual behavioral
health care delivered within an integrated health system
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One field uniquely capable of adopting telehealth was
behavioral health.20,21 Pre-COVID-19 studies suggested
that virtual behavioral health treatment was effective and
comparable to in-person care,22-30 although some patients
had concerns regarding quality and privacy.31 Given the
now-widespread use of telehealth for behavioral health
treatment, it is imperative to assess patient and physician
satisfaction with telehealth in a clinical setting across time.
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across an extended duration. The secondary purpose was to
compare outcomes between virtual and in-person mental
health intensive outpatient treatment programs (IOP). IOP
were targeted because they had parallel virtual and inperson options, thereby allowing comparison of virtual and
in-person formats within a single program type. In contrast,
partial hospitalization programs only briefly offered virtual
treatment, thereby limiting the ability to compare virtual
versus in-person versions of that program.

METHODS

This study design was retrospective and quantitative. Data
were initially collected for internal quality purposes and
included responses to surveys by clinicians and patients
as well as electronic health record (EHR) characteristics.
The study was deemed non-human subject research by the
relevant institutional review board. Virtual visits across
the behavioral health system utilized HIPAA-compliant
telephone or Zoom modalities.
Study Population

The target population for the patient surveys analysis
was all adult patients completing at least one virtual
behavioral health visit for mental health and/or substance
use treatment between May 4, 2020, and July 25, 2021,
within a large integrated health system. This included
all available levels of behavioral health care acuity that
offered a virtual component, meaning virtual partial
hospitalization programs, virtual IOP, and virtual
outpatient programs. Although clinical care teams were
asked to provide all eligible patients with links to the
surveys, the anonymity of the survey responses precluded
confirming which teams were consistently sending
survey links to their patients. Further, patients could enter
treatment more than once, thus potentially resulting in
more than one survey submission per patient. Therefore,
it is unknown which patients received the survey link and
also went on to complete the survey.
The target population for the clinician survey analysis was
all behavioral health clinicians providing virtual mental
health and/or substance use treatment between June 2020
and May 2021. This included psychiatrists, psychologists,
therapists, social workers, and other professionals
providing direct virtual behavioral health care. Although
all clinicians providing virtual treatment were eligible to
take the survey, surveys were sent by clinical leadership
and responses were anonymous. Therefore, it is unknown
whether every leader consistently forwarded the survey
to all of their eligible clinicians and whether all clinicians
who received the survey also completed it.
The study population for the retrospective EHR analysis
included all patients who started mental health IOP

Quality Improvement

treatment on or after April 1, 2021, and were discharged
by July 2, 2021, with data collection starting at the
patient’s first completed visit. This relatively brief time
period was chosen to control for temporal changes in
extraneous factors such as overall treatment program
quality and social/environmental variables (eg, changes
to community-level COVID-19 restrictions).
Data Collection

Patient Surveys: Two surveys were used to collect patient
feedback: a daily survey and a survey at discharge. Each
provider could choose their own process for sending
survey links, such as sending via email or via the health
system’s patient portal. The daily survey asked patients to
rate the quality of their treatment that day on a scale of 1
to 10. This survey was delivered to patients each day after
treatment (Online Appendix A, Survey 1). The discharge
survey was sent to patients after program discharge and
used a Likert scale to collect feedback about ratings and
preferences comparing virtual and in-person treatment
(Online Appendix A, Survey 2).
Anonymous responses were collected in Microsoft
Forms. Patients submitted 2479 responses to the daily
survey, which could be submitted across multiple visits
during treatment, and 414 responses to the discharge
surveys, which were only submitted once per patient at
treatment discharge for each program admission.
Clinician Surveys: Clinicians were surveyed around
every 2 months (Online Appendix A, Survey 3). The
clinician survey was sent via a survey link in an email
from each team member’s clinical leadership 6 times
between August 2020 and May 2021, and 381 responses
were collected overall. The quantitative Likert scale
survey was anonymous, and therefore the number of
unique clinicians represented in this population across
time is unknown. Assuming each clinician respondent
completed no more than one survey for any individual
request, unique clinician participation for each of the 6
survey time points ranged from 37 to 84 responses.
EHR Data: Retrospective patient EHR data were
collected manually to assess no-show, length of stay
(completed visit count within the episode of care), and
program completion rates for patients enrolled in the
virtual or in-person versions of equivalent mental health
IOP at a single psychiatric hospital. All eligible patient
records were assessed, resulting in 116 admissions to inperson mental health IOP treatment and 81 admissions
to virtual mental health IOP treatment, for a total of 197
admissions across 194 unique patients (3 patients were
admitted twice).
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Program completion data were measured as a binary
variable determined by whether the patient successfully
completed the program based on clinical discharge
notes (eg, “Patient completed program,” “Patient lost to
follow-up”). Length of stay was measured as the number
of completed visits within the episode of care. To
calculate no-show rates, data included the total number
of scheduled appointments, appointments attended,
and appointments that were no-shows or cancelled late
(ie, patient did not show up, indicated they were ill, or
indicated they did not have transportation). No-show
rates were calculated by dividing the total number
of no-show/cancelled visits by the total number of
scheduled visits.
Statistical Analyses

Descriptive statistics including frequencies, percentages,
medians, and quartiles were used to summarize data.
Beta regression was used to model proportion data. Chisquared test of association was used to compare groups
of categorical variables. Wilcoxon-Mann-Whitney test
was used to compare groups of continuous variables.
Cochran-Mantel-Haenszel chi-squared test for linear
trend (M2) was used to examine trends in responses to
Likert-type questions over time,32 with its accompanying
Breslow-Day statistic for homogeneous association
used to test conditional independence. JonckheereTerpstra test (Z-score) was used to assess trends in
nonnormal continuous variables over time. Data were
analyzed using Prism version 8.0.0 (GraphPad Sofware)
and SAS 9.4 (SAS Institute Inc.) software. P-values of
≤0.05 were considered statistically significant.

RESULTS

Patient Survey Outcomes

Patient daily surveys demonstrated consistently high
satisfaction ratings (on 1–10 scale) across the 16-month
survey period (Figure 1A). The mean rating over the
study period was 8.9 out of 10. A Jonckheere-Terpstra
test indicated that there was a significant upward trend in
mean ratings over time (Z=5.37; P<0.0001).
Across the 16-month data collection period, most
discharge survey responses (53.6%) indicated that
virtual treatment was very or somewhat similar to
in-person treatment experiences, and there was no
significant trend in the responses over the study period
(M2(1)=0.51; P=0.48) (Figure 1B). Most responses
(61.3%) indicated a preference for virtual treatment over
in-person treatment or indicated no preference (22.4%),
and there was a significant increasing trend in the data
path of preference for virtual care delivery over time
(M2(1)=6.63; P=0.01) (Figure 1C).
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Figure 1. Patient virtual behavioral health survey
responses. Virtual patient daily score submissions
(Panel A) and perceptions at program discharge
(Panels B and C) across time.
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Figure 2. Aggregated clinician
perceptions of virtual behavioral health
treatment across time per responses to
multiple survey questions (Panels A–E).

Clinician Survey Outcomes

Across the study period, the majority of clinician
responses (54.6%) rated virtual treatment as very easy/
easy, and an additional 25.7% considered it neither easy
nor difficult (Figure 2A). There was no significant trend
in perception of ease of implementing virtual treatment
Quality Improvement

across time (M2(1)=1.73; P=0.19). At the inception of
virtual treatment in June 2020, more clinicians preferred
in-person services (49.4%) compared to virtual (31.8%),
yet there was a significant increasing trend of clinician
preference for virtual services over time (M2(1)=21.49;
P<0.0001) (Figure 2B). By the last survey period in May
aah.org/jpcrr

161

Table 1. Patient Demographics and IOP Outcomes (N=197)
Characteristic

In-person IOP,
n=116

Virtual IOP,
n=81

P

Age in years, mean (IQR)

35 (25.3–49.0)

35 (24.0–46.5)

0.78

Sex, n (%)
Female
Male

62 (53.5%)
54 (46.5%)

56 (69.1%)
25 (30.9%)

Race, n (%)
White, not of Hispanic origin
Black, not of Hispanic origin
AI/AN, AAPI, multiracial, or unknown
White, of Hispanic origin

83 (74.1%)
19 (17.0%)
10 (8.9%)
4 (3.6%)

52 (70.3%)
14 (18.9%)
8 (10.8%)
7 (9.5%)

51 (44.0%)
11.0% (0–33.0)
9.5 (6.0–14.0)

49 (60.5%)
6.0% (0–12.0)
11.0 (7.0–15.0)

Attendance outcomes
Completed treatment, n (%)
Rate of no-shows or late cancellation, median (IQR)
Length of stay by visit count, median (IQR)

0.03

0.43

0.02
0.02
<0.001

Note: Categorical data are given as count with percentage and continuous data as median with IQR.
AI/AN, American Indian or Alaskan Native; AAPI, Asian American Pacific Islander; IQR, interquartile range; IOP, intensive
outpatient treatment program.

2021, the majority preferred virtual services (60.0%)
compared to only 13.3% who preferred in-person and
26.7% who had no preference.
There was a significant increase in perceptions of virtual
treatment effectiveness over time, from 13.1% in June
2020 to 30.0% in May 2021 (M2(1)=15.52; P<0.0001)
(Figure 2C). Nearly half of clinicians perceived virtual
and in-person treatments as equally effective. On
average over the study period, most clinicians (74.3%)
indicated they would choose to continue offering virtual
treatment, with a significant upward trend from 61.2%
at study inception to 88.3% at study end (M2(1)=5.77;
P=0.02) (Figure 2D). Clinician ratings of their experience
providing virtual treatment services were high, with a
mean rating of 7.7 out of 10 and a significant upward
trend over time (Z=3.84; P<0.0001) (Figure 2E).
Patient Outcomes and Demographics

Of the 197 mental health IOP patient admissions pulled
from the EHR, 59.9% were female, the majority were
White, and the median age was 35 years (Table 1). Groups
were demographically comparable (race/ethnicity and
age) except that women were significantly more likely to
be in virtual treatment (69.1%) than in-person treatment
(χ2(1)=4.89; P=0.03). Patients in virtual treatment had
significantly higher rates of program completion (60.5%)
than their in-person counterparts (44.0%) (χ2(1)=5.21;
P=0.02).
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Given that women were more likely to receive virtual
treatment and the virtual treatment group was more likely
to complete treatment, the degree of association was
assessed between program type and treatment completion
while controlling for sex. Program completion was
associated with treatment type, independent of patient
sex, and patients in the virtual group had almost twice the
odds of completing treatment compared to their in-person
counterparts regardless of sex (odds ratio: 1.98, 95% CI:
1.10–3.56).
Median visit no-shows and late cancellation rates were
6.0% for virtual admissions and 11.0% for in-person
admissions (P=0.024). Again, sex had no effect on the
no-show and late cancellation rates, and the virtual
group was less likely to miss a scheduled visit compared
to in-person (odds ratio: 0.68, 95% CI: 0.49–0.95;
P=0.025). Patients who did not complete the program had
significantly higher median no-shows and late cancellation
rates (23%) compared to those who completed (6%)
(Z=6.14; P<0.0001). Each unique patient admission in
the virtual group averaged more visits (14) compared to
in-person admissions (9.5) (Z=2.90; P=0.004).

DISCUSSION

Results of study data captured early in the pandemic
through mid-2021 suggest patients were consistently
satisfied with telehealth, which aligns with recent
research.26-28,31,33,34 However, exposure to virtual
treatment resulted in increased preferences for telehealth
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across time. These preferences likely stemmed from
improved treatment access and barrier removal.26,31,35-37
In addition to patients who preferred virtual treatment,
many patients had no preference between virtual and
in-person options. This finding concurs with a previous
study in which 83% of virtual behavioral health patients
had a preference for a hybrid treatment program38 and
suggests opportunities to further improve treatment
using hybrid formats.36
EHR data analyses comparing virtual versus in-person
mental health IOP indicated that virtual patients had
significantly higher rates of attendance, number of
visits, and completion of treatment, which was similar
to literature correlating telehealth programs with
similar or improved attendance rates39,40 and treatment
outcomes.26-30,39,41 This is critical given the correlation of
appropriate and planned transitions between treatment
programs and lower readmission rates.42-44
Women were significantly more likely to be admitted
to virtual treatment than in-person treatment, a finding
similar to other studies45,46 and consistent with women’s
tendency to prefer virtual care as compared to men.47 This
skewing may be due to personal provider preferences, as
clinicians determined program type (virtual or in-person)
based on each patient’s clinical needs, as well as patient
preferences. Although no data were available to assess
why women were more likely to enroll in virtual treatment,
previous studies suggest women may experience more
barriers to travel than men. Specifically, women tend to
have more family/caregiving responsibilities,48 which
have increased during the pandemic,49,50 and women may
be more likely than men to avoid COVID-19 exposure.51
Many clinicians were satisfied with telehealth and
perceived it as effective, with that trend increasing over
time. The percentage of clinicians perceiving virtual
treatment as less effective early in the transition to virtual
was similar to previous reports52 and consistent with data
on clinicians new to virtual care reporting a desire to
return to in-person.36 However, clinician satisfaction with
virtual treatment increased with exposure,9,13,36 as did
the desire to continue telehealth after the pandemic.9,13
Further research is needed to better understand clinicians’
experiences and preferences, as providers are an integral
part of implementing telehealth services.
Limitations

Given the rapid transition to virtual care, survey questions
were not validated using evidence-based questionnaire
methodology. Another limitation is that surveys were
anonymous. This limited the ability to differentiate
responses based on acuity level, reason for treatment, or
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patient/provider demographics and prevented the ability
to track who received the surveys or capture changes
within an individual responder over time. Approximate
sample sizes for the patient and clinician surveys were
not able to be ascertained given the paucity of relevant
population sizes, thus potentially limiting the internal
validity of the results due to potential selection bias
by a nonrepresentative sample of these populations. In
addition, EHR data were retrospective, and therefore
patient assignment to virtual/in-person programs was
not randomized, as evidenced by the higher frequency of
women in virtual treatment. Although analyses controlled
for sex, other variables could similarly be skewed across
groups, and future studies should control for this using
prospective, randomized designs. Future studies also
could include qualitative data to assess reasons for patient
preferences and/or concerns related to virtual treatment,
especially targeting previously identified concerns related
to quality and privacy.31

CONCLUSIONS

The COVID-19 pandemic forced the establishment of
virtual behavioral health as a treatment mechanism.
This long-term study found that both behavioral health
patients and clinicians perceived virtual treatment as
appealing and effective. Importantly, virtual care had
better attendance outcomes compared to in-person care,
suggesting that virtual behavioral health treatments may
be superior for some patients.
Patient-Friendly Recap
• As the COVID-19 pandemic shifted more care
delivery to “telehealth,” those receiving or providing
treatment for mental health conditions increased
their use of virtual visits.
• Authors assessed changes in patient and clinician
satisfaction with virtual behavioral health visits
over time and also compared program attendance
and completion rates for virtual versus in-person
treatment.
• They found that patients and clinicians both
perceived virtual behavioral health treatment as
appealing and effective. Moreover, the superior
outcomes seen from virtual care suggest such visits
should continue to be offered after the pandemic.
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